Literature DB >> 5588

Gastric acid inactivation of erythromycin stearate in solid dosage forms.

B G Boggiano, M Gleeson.   

Abstract

The effect of hydrochloric acid at pH 1.2-3.2 ON ERYTHROMYCIN STEARATE AND COMMERCIAL DOSAGE FORMS OF ERYTHROMYCIN STEARATE WAS STUDIED. Under all conditions examined, erythromycin was readily dissolved from the stearate as hydrochloride, and rapidly lost its biological activity in solution. The inclusion of pepsin in the test systems did not affect the results. Although formulation differences somewhat affected the rate of destruction, acid lability was exhibited by all products examined, except enteric-coated tablets. Amounts of acid considered to be normal in the fasting stomach contents of adults during the time likely for a dose to remain in the stomach caused 70-90% destruction within 15 min after the shells started to rupture. Amounts of hydrochloric acid appreciably less than 1 mEq, representing abnormally small quantities even in the fasting state, caused destruction ranging from 30 to 70% of the doses in 15 min. These results are not reconcilable with published statements that the sensitivity of erythromycin to gastric acid is overcome by providing the antibiotic in the form of stearate salt.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 5588     DOI: 10.1002/jps.2600650406

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy.

Authors:  S Krasniqi; P Matzneller; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

2.  Single-dose fasting bioequivalence assessment of erythromycin stearate tablets in man.

Authors:  G J Yakatan; W J Poynor; R G Harris; A Martin; R G Leonard; A H Briggs; J T Doluisio
Journal:  J Pharmacokinet Biopharm       Date:  1979-08

3.  Concentrations of erythromycin, 2'-acetyl erythromycin, and their anhydro forms in plasma and tonsillar tissue after repeated dosage of erythromycin stearate and erythromycin acistrate.

Authors:  A Gordin; P T Männistö; R Antikainen; S Savolainen; J Ylikoski; P Kokkonen; V Rauramaa
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

4.  Evaluation of the intestinal absorption of erythromycin in man: absolute bioavailability and comparison with enteric coated erythromycin.

Authors:  A A Somogyi; F Bochner; D Hetzel; D B Williams
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

5.  Influence of study design in assessing food effects on absorption of erythromycin base and erythromycin stearate.

Authors:  A R DiSanto; D J Chodos
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

6.  Intersubject and dose-related variability after intravenous administration of erythromycin.

Authors:  K L Austin; L E Mather; C R Philpot; P J McDonald
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

7.  Ineffectiveness of erythromycin for treatment of Haemophilus vaginalis-associated vaginitis: possible relationship to acidity of vaginal secretions.

Authors:  M A Durfee; P S Forsyth; J A Hale; K K Holmes
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

8.  The influence of food on the bioavailability of new formulations of erythromycin stearate and base.

Authors:  J Rutland; N Berend; G E Marlin
Journal:  Br J Clin Pharmacol       Date:  1979-10       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.